HK1165698A1 - Use of eicosapentaenoic acid ethyl ester for treating hypertriglyceridemia - Google Patents

Use of eicosapentaenoic acid ethyl ester for treating hypertriglyceridemia

Info

Publication number
HK1165698A1
HK1165698A1 HK12106100.0A HK12106100A HK1165698A1 HK 1165698 A1 HK1165698 A1 HK 1165698A1 HK 12106100 A HK12106100 A HK 12106100A HK 1165698 A1 HK1165698 A1 HK 1165698A1
Authority
HK
Hong Kong
Prior art keywords
eicosapentaenoic acid
ethyl ester
acid ethyl
treating hypertriglyceridemia
treating
Prior art date
Application number
HK12106100.0A
Other languages
English (en)
Inventor
Mehar Manku
Ian Osterloh
Pierre Wicker
Rene Braeckman
Paresh Soni
Original Assignee
Amarin Pharmaceuticals Ie Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42102041&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1165698(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amarin Pharmaceuticals Ie Ltd filed Critical Amarin Pharmaceuticals Ie Ltd
Publication of HK1165698A1 publication Critical patent/HK1165698A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16Z—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS, NOT OTHERWISE PROVIDED FOR
    • G16Z99/00—Subject matter not provided for in other main groups of this subclass

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK12106100.0A 2009-02-10 2012-06-21 Use of eicosapentaenoic acid ethyl ester for treating hypertriglyceridemia HK1165698A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15129109P 2009-02-10 2009-02-10
US17375509P 2009-04-29 2009-04-29
PCT/US2010/023638 WO2010093634A1 (en) 2009-02-10 2010-02-09 Use of eicosapentaenoic acid ethyl ester for treating hypertriglyceridemia

Publications (1)

Publication Number Publication Date
HK1165698A1 true HK1165698A1 (en) 2012-10-12

Family

ID=42102041

Family Applications (2)

Application Number Title Priority Date Filing Date
HK12106100.0A HK1165698A1 (en) 2009-02-10 2012-06-21 Use of eicosapentaenoic acid ethyl ester for treating hypertriglyceridemia
HK16114664A HK1226307A1 (zh) 2009-02-10 2016-12-23 用於治療高甘油三酯血症的二十碳五烯酸乙酯

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK16114664A HK1226307A1 (zh) 2009-02-10 2016-12-23 用於治療高甘油三酯血症的二十碳五烯酸乙酯

Country Status (24)

Country Link
US (29) US8293727B2 (xx)
EP (5) EP2395991B1 (xx)
KR (2) KR101383006B1 (xx)
AU (1) AU2010213899B2 (xx)
BR (1) BRPI1007518A2 (xx)
CA (3) CA2751576C (xx)
CY (2) CY1122628T1 (xx)
DK (3) DK3037089T3 (xx)
ES (3) ES2769926T3 (xx)
HK (2) HK1165698A1 (xx)
HR (3) HRP20130811T1 (xx)
HU (1) HUE048299T2 (xx)
LT (2) LT3037089T (xx)
MX (1) MX2011008448A (xx)
NZ (1) NZ594395A (xx)
PH (1) PH12015500407B1 (xx)
PL (3) PL2395991T3 (xx)
PT (3) PT3037089T (xx)
RU (2) RU2505292C2 (xx)
SG (3) SG10201400685SA (xx)
SI (3) SI2395991T1 (xx)
SM (1) SMT201300095B (xx)
WO (1) WO2010093634A1 (xx)
ZA (1) ZA201105612B (xx)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
PL2334295T3 (pl) 2008-09-02 2017-12-29 Amarin Pharmaceuticals Ltd Kompozycja farmaceutyczna zawierająca kwas eikozapentaenowy i kwas nikotynowy oraz sposoby jej zastosowania
PT2376077T (pt) 2009-01-12 2017-06-23 Biokier Inc Composição e método para tratamento de diabetes
US9314444B2 (en) 2009-01-12 2016-04-19 Biokier, Inc. Composition and method for treatment of NASH
US9006288B2 (en) 2009-01-12 2015-04-14 Biokier, Inc. Composition and method for treatment of diabetes
MX2011008448A (es) 2009-02-10 2012-02-28 Amarin Pharma Inc Uso de ester etilico del acido eisosapentaenoico para tratar hipertrigliceridemia.
CN102458109B (zh) 2009-04-29 2015-02-11 阿马里纳制药公司 稳定的药物组合物和使用其的方法
EP2424521A4 (en) 2009-04-29 2015-03-04 Amarin Pharmaceuticals Ie Ltd PHARMACEUTICAL COMPOSITIONS COMPRISING EPA AND CARDIOVASCULAR AGENT AND METHODS OF USE
KR102012111B1 (ko) 2009-06-15 2019-08-19 아마린 파마, 인크. 병용 스타틴 요법을 받는 대상체에서 ｌｄｌ－ｃ 수준을 상승시키지 않으면서 트리글리세리드를 저하시키기 위한 조성물 및 방법
BR112012006437A2 (pt) 2009-09-23 2016-04-19 Biokier Inc composições e métodos para tratamento do diabetes e outros distúrbios
SG10201405994UA (en) 2009-09-23 2014-10-30 Amarin Pharmaceuticals Ie Ltd Pharmaceutical Composition Comprising Omega-3 Fatty Acid And Hydroxy-derivative Of A Statin And Methods Of Using Same
WO2011087981A2 (en) 2010-01-15 2011-07-21 E. I. Du Pont De Nemours And Company Clinical benefits of eicosapentaenoic acid in humans
EP2542060B1 (en) * 2010-03-04 2019-10-02 Amarin Pharmaceuticals Ireland Limited Compositions for treating and/or preventing cardiovascular disease
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
NZ712068A (en) * 2010-11-29 2017-03-31 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US8951514B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
US9119826B2 (en) 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
US8952000B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
US8715648B2 (en) 2011-02-16 2014-05-06 Pivotal Therapeutics Inc. Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
EP2775837A4 (en) * 2011-11-07 2015-10-28 Amarin Pharmaceuticals Ie Ltd METHODS OF TREATING HYPERTRIGLYCERIDEMIA
US11291643B2 (en) * 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
PL2800563T3 (pl) 2012-01-06 2018-12-31 Omthera Pharmaceuticals Inc. Wzbogacone w DPA kompozycje wielonienasyconych kwasów tłuszczowych omega-3 w postaci wolnego kwasu
WO2013103958A1 (en) * 2012-01-06 2013-07-11 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject
EP2846790A4 (en) * 2012-02-14 2016-03-23 Photonz Corp Ltd METHOD OF SUPERVISING THE CONSUMPTION OF AN ALICAMENT COMPRISING EICOSAPENTAENOIC ACID FOR THE PREVENTION AND / OR MANAGEMENT OF A DISEASE OR A CONDITION OF THE DISEASE
JP6173437B2 (ja) 2012-05-07 2017-08-02 オムセラ・ファーマシューティカルズ・インコーポレイテッド スタチン及びω−３脂肪酸の組成物
KR102125034B1 (ko) * 2012-05-15 2020-06-19 모치다 세이야쿠 가부시키가이샤 고혈중 고감도 c반응성 단백질 환자의 심혈관 질병 1차 예방제
EP2861227A4 (en) 2012-06-17 2016-01-27 Matinas Biopharma Inc OMEGA-3 PENTAIC ACID COMPOSITIONS AND METHODS OF USE
US20140005265A1 (en) * 2012-06-29 2014-01-02 Amarin Pharmaceuticals Ireland Limited Methods for treating hypertriglyceridemia
WO2014004993A2 (en) * 2012-06-29 2014-01-03 Amarin Pharmaceuticals Ireland Limited Methods of reducing ldl-p
SG11201408769QA (en) 2012-06-29 2015-01-29 Amarin Pharmaceuticals Ie Ltd Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
US20140004183A1 (en) * 2012-06-29 2014-01-02 Amarin Pharmaceuticals Ireland Limited Methods for treating cardiovascular disease in statin-tolerant subjects
WO2014050692A1 (ja) * 2012-09-28 2014-04-03 持田製薬株式会社 糖尿病新規発症低減用組成物
US20150265566A1 (en) 2012-11-06 2015-09-24 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
US10123986B2 (en) 2012-12-24 2018-11-13 Qualitas Health, Ltd. Eicosapentaenoic acid (EPA) formulations
US9629820B2 (en) 2012-12-24 2017-04-25 Qualitas Health, Ltd. Eicosapentaenoic acid (EPA) formulations
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US20140213648A1 (en) * 2012-12-31 2014-07-31 Amarin Pharmaceuticals Ireland Limited Methods of increasing epa blood levels
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140221452A1 (en) * 2013-02-06 2014-08-07 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and 5-htp and methods of use thereof
US20140221358A1 (en) * 2013-02-06 2014-08-07 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and diazoxide and methods of use thereof
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
WO2014143275A1 (en) * 2013-03-13 2014-09-18 Matinas Biopharma Inc. Omega-3 pentaenoic acid compositions and methods of use
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
KR102039522B1 (ko) * 2013-06-03 2019-11-26 휴렛-팩커드 디벨롭먼트 컴퍼니, 엘.피. 근거리 무선 통신(ｎｆｃ)을 이용한 ｎｆｃ 태그의 기록방법 및 장치
US20140357717A1 (en) * 2013-06-04 2014-12-04 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
JP6804823B2 (ja) * 2013-10-14 2020-12-23 アリゾナ・ボード・オブ・リージェンツ・オン・ビハーフ・オブ・アリゾナ・ステイト・ユニバーシティーＡｒｉｚｏｎａ Ｂｏａｒｄ ｏｆ Ｒｅｇｅｎｔｓ ｏｎ ｂｅｈａｌｆ ｏｆ Ａｒｉｚｏｎａ Ｓｔａｔｅ Ｕｎｉｖｅｒｓｉｔｙ 白金錯体およびデバイス
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10547995B2 (en) * 2015-04-30 2020-01-28 Lg Electronics Inc. Method and device for transmitting/receiving data using Bluetooth mesh network
US10183044B2 (en) 2015-05-15 2019-01-22 P Tech, Llc Systems and methods for thrombosis prevention
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
TW201900160A (zh) 2017-05-19 2019-01-01 愛爾蘭商艾瑪琳製藥愛爾蘭有限公司 用於降低腎功能下降之個體中的三酸甘油酯之組合物及方法
JP2021501210A (ja) 2017-10-30 2021-01-14 モントリオール ハート インスティテュート 血漿コレステロールの上昇を処置する方法
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
KR102296068B1 (ko) 2018-09-24 2021-09-02 애머린 파마슈티칼스 아일랜드 리미티드 대상체에서 심혈관 사건의 위험도를 감소시키는 방법
KR20240012390A (ko) 2021-04-21 2024-01-29 애머린 파마슈티칼스 아일랜드 리미티드 심부전의 위험을 감소시키는 방법

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4377526A (en) 1981-05-15 1983-03-22 Nippon Suisan Kaisha, Ltd. Method of purifying eicosapentaenoic acid and its esters
CA1239587A (en) 1983-10-24 1988-07-26 David Rubin Combined fatty acid composition for lowering blood cholestrol and triglyceride levels
US4526902A (en) 1983-10-24 1985-07-02 Century Laboratories, Inc. Combined fatty acid composition for treatment or prophylaxis of thrombo-embolic conditions
JPS6135356A (ja) * 1984-07-27 1986-02-19 Nippon Oil & Fats Co Ltd 血液脂質脂肪酸の分析方法
US4920098A (en) 1986-09-17 1990-04-24 Baxter International Inc. Nutritional support or therapy for individuals at risk or under treatment for atherosclerotic vascular, cardiovascular, and/or thrombotic diseases
US5252333A (en) 1987-04-27 1993-10-12 Scotia Holdings Plc Lithium salt-containing pharmaceutical compositions
US5198468A (en) 1987-06-24 1993-03-30 Efamol Holdings Plc Essential fatty acid composition
US4843095A (en) 1987-08-07 1989-06-27 Century Laboratories, Inc. Free fatty acids for treatment or propyhlaxis of rheumatoid arthritis arthritis
GB8819110D0 (en) 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
IE63225B1 (en) 1988-09-13 1995-04-05 Efamol Holdings Use of fatty acids in the treatment of myalgic encephalomyelitis
GB2223943A (en) 1988-10-21 1990-04-25 Tillotts Pharma Ag Oral disage forms of omega-3 polyunsaturated acids
US4935243A (en) 1988-12-19 1990-06-19 Pharmacaps, Inc. Chewable, edible soft gelatin capsule
JP2839276B2 (ja) 1989-01-23 1998-12-16 日本分光工業株式会社 超臨界流体抽出・分離方法及び装置
US5457130A (en) 1989-03-20 1995-10-10 Cancer Research Campaign Technology Limited Eicosapentaenoic acid used to treat cachexia
GB8906369D0 (en) 1989-03-20 1989-05-04 Tisdale Michael J Eicosapentaenoic acid
CA2043615C (en) 1990-06-04 2001-08-14 Kazuhiko Hata Method of producing eicosapentaenoic acid or the ester derivative thereof
GB9012651D0 (en) 1990-06-06 1990-07-25 Efamol Holdings Essential fatty acid treatment
JP3103588B2 (ja) 1990-11-16 2000-10-30 持田製薬株式会社 リポプロテイン（ａ）低下剤
SE9101642D0 (sv) 1991-05-30 1991-05-30 Kabi Pharmacia Ab Phospholipids
US5215630A (en) 1991-06-04 1993-06-01 Nippon Suisan Kaisha, Ltd. Method of purifying eicosapentaenoic acid or the ester derivative thereof by fractional distillation
AU2384292A (en) * 1991-07-30 1993-03-02 North Carolina State University Method and apparatus for measuring blood lipoprotein levels by nmr spectroscopy
DE4133694C2 (de) 1991-10-11 1993-10-07 Fresenius Ag Verwendung einer Emulsion mit mehrfach ungesättigten Fettsären zur i.v.-Verabreichung zur Behandlung von Hauterkrankungen
JP3400466B2 (ja) 1991-10-28 2003-04-28 日本水産株式会社 高純度エイコサペンタエン酸またはそのエステルの製造方法
JPH0649479A (ja) 1992-07-28 1994-02-22 Maruha Corp ω−３不飽和脂肪酸系化合物の安定化法
US5888541A (en) 1992-08-21 1999-03-30 Scotia Holdings Plc Fatty acid treatment
GB9217780D0 (en) 1992-08-21 1992-10-07 Efamol Holdings Fatty acid treatment
GB9300125D0 (en) 1993-01-06 1993-03-03 Scotia Holdings Plc Compositions containing esters of unsaturated fatty acids
WO1994028891A1 (en) 1993-06-04 1994-12-22 Martek Biosciences Corporation Method of treating coronary vascular disease using docosahexaenoic acid
GB9403857D0 (en) 1994-03-01 1994-04-20 Scotia Holdings Plc Fatty acid derivatives
US5760081A (en) 1994-05-10 1998-06-02 The General Hospital Corporation Omega 3 fatty acids in the prevention of ventricular fibrillation
AU711482B2 (en) 1994-06-28 1999-10-14 Scotia Holdings Plc Compositions for treatment of diabetic complications
IT1274734B (it) 1994-08-25 1997-07-24 Prospa Bv Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti
MY118354A (en) 1995-05-01 2004-10-30 Scarista Ltd 1,3-propane diol derivatives as bioactive compounds
GB9519661D0 (en) 1995-09-27 1995-11-29 Scotia Holdings Plc Fatty acid treatment
WO1997039759A2 (en) 1996-04-24 1997-10-30 Brigham And Women's Hospital Omega-3 fatty acids and omega-3 phosphatidylcholine in the treatment of bipolar disorder
TW425285B (en) 1996-06-10 2001-03-11 Viva America Marketing Inc Fish oil and garlic nutritive supplement
US5861399A (en) 1996-07-17 1999-01-19 Heart Care Partners Methods and compositions for the rapid and enduring relief of inadequate myocardial function
US20020055539A1 (en) 1996-10-02 2002-05-09 Bockow Barry I. Compositions and methods for treating cardiovascular conditions
NZ334852A (en) 1996-10-11 2001-05-25 Scotia Holdings Plc Use and preparation containing eicosapentaenoic acid (EPA; 20:5n-3) for treating schizophrenia
US20010006644A1 (en) 1997-07-31 2001-07-05 David J. Bova Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
WO1999022719A1 (fr) 1997-10-30 1999-05-14 Morishita Jintan Co., Ltd. Preparation de capsule contenant un acide gras insature ou un derive de celui-ci, et procede de fabrication
EP1039893B1 (en) 1997-12-10 2011-02-02 Cyclosporine Therapeutics Limited Pharmaceutical compositions containing an omega-3 fatty acid oil
US20020055529A1 (en) 1998-12-02 2002-05-09 Bisgaier Charles Larry Method for treating alzheimer's disease
GB9901809D0 (en) 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
US20030104048A1 (en) 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
US6193999B1 (en) 1999-03-01 2001-02-27 Banner Pharmacaps, Inc. Gum acacia substituted soft gelatin capsules
PT1072198E (pt) 1999-07-28 2008-06-17 Swiss Caps Rechte & Lizenzen Preparado, especialmente para utilização como medicamento e/ou como suplemento alimentar
EP1211955A1 (en) 1999-08-30 2002-06-12 Ocean Nutrition Canada Ltd. A nutritional supplement for lowering serum triglyceride and cholesterol levels
ATE305810T1 (de) 2000-05-22 2005-10-15 Pro Aparts Investimentos E Con Fettsäure enthaltende pharmazeutische zusammensetzung die wenigstens 80 gew. epa und dha enthält
GB0016045D0 (en) 2000-06-29 2000-08-23 Laxdale Limited Therapeutic combinations of fatty acids
MXPA03001419A (es) 2000-08-15 2003-06-06 Pfizer Prod Inc Combinacion terapeutica de un inhibidor de la proteina de transferencia de esteres de colesterol y atorvastatina.
ITMI20010129A1 (it) 2001-01-25 2002-07-25 Pharmacia & Upjohn Spa Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
GB0111282D0 (en) 2001-05-09 2001-06-27 Laxdale Ltd Potentiation of therapeutic effects of fatty acids
CN1268328C (zh) 2001-05-30 2006-08-09 拉克斯戴尔有限公司 辅酶q与二十碳五烯酸(epa)
ITMI20012384A1 (it) 2001-11-12 2003-05-12 Quatex Nv Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori
ITMI20020269A1 (it) 2002-02-12 2003-08-12 Victorix Assets Ltd Uso di steri etilici di acidi poliinsaturi omega-3 in pazienti con insufficienza cardiaca
HUP0200686A2 (hu) 2002-02-22 2003-09-29 EURO- "H" Beruházásszervezż és Ingatlanhasznosító Kft. Elektronikus berendezés és eljárás számsorozat eltalálására irányuló játékokban való részvételre kommunikációs berendezésen keresztül
US20030166614A1 (en) 2002-03-01 2003-09-04 Harrison Stanley F. Method for reducing cholesterol and triglycerides
CA2390820A1 (en) * 2002-06-17 2003-12-17 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
US7314643B2 (en) 2002-08-20 2008-01-01 Nikken Chemicals Co., Ltd. Soft capsule preparation
KR101045035B1 (ko) 2002-11-22 2011-06-30 니폰스이산가부시키가이샤 산화 안정성이 향상된 이중결합을 가진 유기물을 함유하는조성물
GB0228079D0 (en) 2002-12-02 2003-01-08 Laxdale Ltd Huntington's Disease
AU2004216856A1 (en) 2003-03-05 2004-09-16 Solvay Pharmaceuticals Gmbh Use of omega-3-fatty acids in the treatment of diabetic patients
EP1605781A1 (en) 2003-03-18 2005-12-21 Novartis AG Compositions comprising fatty acids and amino acids
ITMI20032247A1 (it) 2003-11-19 2005-05-20 Tiberio Bruzzese Interazione di derivati polari di composti insaturi con substrati inorganici
GB2409644B (en) 2003-12-31 2005-12-21 Igennus Ltd Formulation comprising eicosapentaenoic acid or an ester thereof and a triterpene or an ester thereof
US7022713B2 (en) 2004-02-19 2006-04-04 Kowa Co., Ltd. Hyperlipemia therapeutic agent
US20050272095A1 (en) * 2004-05-19 2005-12-08 Ppd Biomarker Discovery Sciences, Llc Methods of identifying biomarkers
JP2007284350A (ja) 2004-07-27 2007-11-01 Takeda Chem Ind Ltd 糖尿病治療剤
ITRM20040395A1 (it) 2004-08-03 2004-11-03 Sigma Tau Ind Farmaceuti Composizione comprendente statine e acidi grassi omega 3.
US7642287B2 (en) 2004-08-06 2010-01-05 Transform Pharmaceuticals, Inc. Statin pharmaceutical compositions and related methods of treatment
US20080070958A1 (en) 2004-09-13 2008-03-20 Santen Pharmaceutical Co., Ltd. Therapeutic Agent for Keratoconjunctival Disorder
CN1759834B (zh) * 2004-09-17 2010-06-23 中国医学科学院医药生物技术研究所 黄连素或其与辛伐他汀联合在制备用于预防或治疗与血脂有关疾病或症状的产品中用途
US20080113031A1 (en) 2004-09-27 2008-05-15 Joey Moodley Minicapsule Formulations
JP5491697B2 (ja) 2004-10-15 2014-05-14 フォトンズ コーポレイション リミテッド 高レベルオメガ−３および低レベル飽和脂肪酸を含む組成物
FR2878747B1 (fr) 2004-12-03 2007-03-30 Pierre Fabre Medicament Sa Utilisation d'acide(s) gras omega-3 pour le traitement de l'hypercholesterolemie causee par un traitement anti-retroviral chez les patients infectes par le vih
US20070191467A1 (en) 2004-12-06 2007-08-16 Reliant Pharmaceutical, Inc. Statin and omega-3 fatty acids for lipid therapy
US20060211762A1 (en) 2004-12-06 2006-09-21 Rongen Roelof M Omega-3 fatty acids and dyslipidemic agent for lipid therapy
US20060135610A1 (en) 2004-12-22 2006-06-22 Bortz Jonathan D Cardiovascular compositions
GB2421909A (en) 2004-12-23 2006-07-12 Laxdale Ltd Pharmaceutical compositions comprising EPA and methods of use
US20060189682A1 (en) * 2005-02-02 2006-08-24 Payne Joseph E Water soluble prodrugs of COX-2 inhibitors
MX2007011031A (es) 2005-03-08 2008-04-21 Reliant Pharmaceuticals Inc Tratamiento con estatina y acidos grasos omega-3 y un producto de combinacion de los mismos.
CA2570763C (en) 2005-07-08 2011-08-23 Mochida Pharmaceutical Co., Ltd. Composition for preventing onset of cardiovascular events
RU2290185C1 (ru) * 2005-07-26 2006-12-27 Дмитрий Николаевич Мясников Композиция для нормализации липидного обмена и снижения массы тела и способ её получения
WO2007016256A2 (en) 2005-07-28 2007-02-08 Reliant Pharmaceuticals, Inc. Treatment with dihydropyridine calcium channel blockers and omega-3 fatty acids and a combination product thereof
ITMI20051560A1 (it) 2005-08-10 2007-02-11 Tiberio Bruzzese Composizione di acidi grassi n-3 con elevata concentrazione di epa e-o dha e contenente acidi grassi n-6
US20090227602A1 (en) 2005-10-28 2009-09-10 John Griffin Compositions and treatments for inhibiting kinase and/or hmg-coa reductase
US20070104779A1 (en) 2005-11-07 2007-05-10 Rongen Roelof M Treatment with omega-3 fatty acids and products thereof
KR101292573B1 (ko) 2005-11-11 2013-08-12 모치다 세이야쿠 가부시키가이샤 젤리 조성물
CA2634139C (en) 2005-12-20 2015-06-23 Cenestra, Llc. Omega 3 fatty acid formulations
ATE509624T1 (de) 2005-12-23 2011-06-15 Nutricia Nv Zusammensetzung enthaltend mehrfach ungesättigte fettsäuren, proteine, mangan und/oder molybden und nukleotide/nukleoside, zur behandlung von demenz
US7498359B2 (en) * 2006-02-07 2009-03-03 Mochida Pharmaceutical., Ltd. Composition and method for preventing recurrence of stroke
WO2007128801A1 (en) 2006-05-08 2007-11-15 Novartis Ag Combination of organic compounds
WO2007142118A1 (ja) 2006-05-31 2007-12-13 Mochida Pharmaceutical Co., Ltd. 多重リスク患者の心血管イベント発症予防用組成物
NZ573719A (en) 2006-07-05 2011-08-26 Photonz Corp Ltd Production of ultrapure eicosapentaenoic acid and polar lipids from largely heterotrophic culture of nitzschia laevis
US20090304784A1 (en) 2006-07-28 2009-12-10 V. Mane Fils Seamless capsules containing high amounts of polyunsaturated fatty acids and a flavouring component
EA018734B1 (ru) 2006-10-10 2013-10-30 Релайэнт Фармасьютикалз, Инк. СТАТИН И ОМЕГА-3 ЖИРНЫЕ КИСЛОТЫ ДЛЯ СНИЖЕНИЯ УРОВНЕЙ Apo-B
US20080125490A1 (en) 2006-11-03 2008-05-29 My Svensson Treatment and prevention of cardiovascular disease in patients with chronic kidney disease by administering Omega-3 Fatty Acids
US20080306154A1 (en) 2006-11-03 2008-12-11 My Svensson Treatment and prevention of major adverse cardiovascular events or major coronary evens by administering Omega-3 fatty acids
JP5345402B2 (ja) 2007-01-17 2013-11-20 持田製薬株式会社 血栓もしくは塞栓に関連する疾患の予防又は治療用組成物
US20100055175A1 (en) 2007-03-06 2010-03-04 James Nugent Soft gelatin capsule shells containing oil soluble flavoring and methods of making the same
WO2009004999A1 (ja) 2007-06-29 2009-01-08 Takeda Pharmaceutical Company Limited シームレスカプセル
US20090182049A1 (en) 2008-01-16 2009-07-16 Joar Arild Opheim Pharmaceutical Composition and Method for Treating Hypertriglyceridemia and Hypercholesterolemia in Humans
CA2724983A1 (en) 2008-05-20 2009-11-26 Mochida Pharmaceutical Co., Ltd. Composition for preventing cardiovascular event in high-risk patient
PL2334295T3 (pl) 2008-09-02 2017-12-29 Amarin Pharmaceuticals Ltd Kompozycja farmaceutyczna zawierająca kwas eikozapentaenowy i kwas nikotynowy oraz sposoby jej zastosowania
MX2011008448A (es) 2009-02-10 2012-02-28 Amarin Pharma Inc Uso de ester etilico del acido eisosapentaenoico para tratar hipertrigliceridemia.
CN102458109B (zh) 2009-04-29 2015-02-11 阿马里纳制药公司 稳定的药物组合物和使用其的方法
KR102012111B1 (ko) 2009-06-15 2019-08-19 아마린 파마, 인크. 병용 스타틴 요법을 받는 대상체에서 ｌｄｌ－ｃ 수준을 상승시키지 않으면서 트리글리세리드를 저하시키기 위한 조성물 및 방법
MY164729A (en) 2010-11-04 2018-01-30 Hoffmann La Roche A composition comprising s-[2- ( [ [1- (2-ethylbutyl) - cyclohexyl] - carbonyl]amino)phenyl] 2-methylpropanethioate and croscarmellose sodium
US20140004183A1 (en) * 2012-06-29 2014-01-02 Amarin Pharmaceuticals Ireland Limited Methods for treating cardiovascular disease in statin-tolerant subjects

Also Published As

Publication number Publication date
EP2395991B1 (en) 2013-05-29
US8431560B1 (en) 2013-04-30
US20130004568A1 (en) 2013-01-03
EP3865128A1 (en) 2021-08-18
KR101383006B1 (ko) 2014-04-08
US20130171250A1 (en) 2013-07-04
PH12015500407A1 (en) 2015-09-21
US20180185320A1 (en) 2018-07-05
SG10201400685SA (en) 2015-01-29
BRPI1007518A2 (pt) 2018-02-20
US8314086B2 (en) 2012-11-20
US20100311834A1 (en) 2010-12-09
AU2010213899B2 (en) 2014-02-06
CA3089847C (en) 2024-04-09
CA2751576A1 (en) 2010-08-19
LT3037089T (lt) 2020-01-10
US20210069142A1 (en) 2021-03-11
EP3616694A1 (en) 2020-03-04
RU2013154780A (ru) 2015-06-20
US8377920B2 (en) 2013-02-19
ZA201105612B (en) 2012-10-31
CY1122629T1 (el) 2021-03-12
US20120108663A1 (en) 2012-05-03
EP2596786A1 (en) 2013-05-29
PT2395991E (pt) 2013-09-03
DK3037089T3 (da) 2020-01-20
KR20110110321A (ko) 2011-10-06
DK2395991T3 (da) 2013-09-02
ES2768091T3 (es) 2020-06-19
PT3037089T (pt) 2020-03-04
WO2010093634A1 (en) 2010-08-19
US20120039997A1 (en) 2012-02-16
HRP20200068T1 (hr) 2020-04-03
US20120237594A1 (en) 2012-09-20
CA3008079A1 (en) 2010-08-19
US8415335B2 (en) 2013-04-09
PT2596786T (pt) 2020-03-04
US8324195B2 (en) 2012-12-04
US8524698B2 (en) 2013-09-03
US8293728B2 (en) 2012-10-23
RU2011137415A (ru) 2013-03-20
US8518929B2 (en) 2013-08-27
US8546372B2 (en) 2013-10-01
US8440650B1 (en) 2013-05-14
US20120156285A1 (en) 2012-06-21
US20130102674A1 (en) 2013-04-25
US20130017256A1 (en) 2013-01-17
US8426399B2 (en) 2013-04-23
SI2395991T1 (sl) 2013-12-31
EP3037089A1 (en) 2016-06-29
EP2596786B1 (en) 2019-11-27
US20120157530A1 (en) 2012-06-21
ES2769926T3 (es) 2020-06-29
US20120093924A1 (en) 2012-04-19
US20120108660A1 (en) 2012-05-03
PL2596786T3 (pl) 2020-06-01
US20130004566A1 (en) 2013-01-03
SMT201300095B (it) 2013-11-08
US8399446B2 (en) 2013-03-19
RU2019111131A (ru) 2020-10-15
SI2596786T1 (sl) 2020-03-31
HK1226307A1 (zh) 2017-09-29
PH12015500407B1 (en) 2015-09-21
RU2686315C2 (ru) 2019-04-25
MX2011008448A (es) 2012-02-28
RU2505292C2 (ru) 2014-01-27
US20170119722A1 (en) 2017-05-04
CY1122628T1 (el) 2021-03-12
HRP20200065T1 (hr) 2020-04-03
HRP20130811T1 (xx) 2013-09-30
KR20140007973A (ko) 2014-01-20
US20130331447A1 (en) 2013-12-12
US20130171249A1 (en) 2013-07-04
US20110288171A1 (en) 2011-11-24
LT2596786T (lt) 2020-01-10
US20210251941A1 (en) 2021-08-19
US20130004567A1 (en) 2013-01-03
US8357677B1 (en) 2013-01-22
US8367652B2 (en) 2013-02-05
NZ594395A (en) 2014-01-31
CA3008079C (en) 2020-09-22
US20200246300A1 (en) 2020-08-06
SI3037089T1 (sl) 2020-03-31
AU2010213899A1 (en) 2011-08-25
PL2395991T3 (pl) 2013-11-29
US20210046036A1 (en) 2021-02-18
EP2395991A1 (en) 2011-12-21
US20240024277A1 (en) 2024-01-25
US20190038590A1 (en) 2019-02-07
SG173612A1 (en) 2011-09-29
US20130096197A1 (en) 2013-04-18
SG10201610916SA (en) 2017-02-27
US20130005809A1 (en) 2013-01-03
US20130164375A1 (en) 2013-06-27
US8318715B2 (en) 2012-11-27
PL3037089T3 (pl) 2020-06-01
CA2751576C (en) 2018-07-03
ES2426132T3 (es) 2013-10-21
CA3089847A1 (en) 2010-08-19
EP3037089B1 (en) 2019-11-27
US20120108659A1 (en) 2012-05-03
DK2596786T3 (da) 2020-02-24
HUE048299T2 (hu) 2020-07-28
US8293727B2 (en) 2012-10-23

Similar Documents

Publication Publication Date Title
HRP20130811T1 (xx) Upotreba etilnog estera ikozapentaenske kiseline u lijeäśenju hipertrigliceridemije
CY1123749T1 (el) Μεθοδοι μειωσης του κινδυνου καρδιαγγειακου γεγονοτος σε ενα υποκειμενο επι θεραπειας στατινης χρησιμοποιωντας αιθυλ εστερα εικοσαπενταενοϊκου οξεος
ECSP10010289A (es) Régimen de dosificación asociado con ésteres de paliperidona inyectables de acción prolongada
EP3682875A3 (en) Methods of treating pediatric metabolic syndrome
NZ720946A (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
MX2012003555A (es) Composicion farmaceutica que comprende acido graso omega-3 y derivado hidroxi de una estatina y metodos para usar la misma.
WO2014004993A3 (en) Methods of reducing ldl-p
MX348705B (es) Composiciones farmacéuticas y métodos de administración relacionados.
NZ618734A (en) Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
CY1115725T1 (el) Ενωσεις, συνθεσεις και μεθοδοι για την θεραπευτικη αγωγη των βητα-αμυλοειδικων ασθενειων και συνουκλεϊνοπαθειων
WO2012023623A3 (ja) ハンター症候群の治療剤
EA201270071A1 (ru) Способ лечения пациента, нуждающегося в аспириновой терапии
MX2010008433A (es) Uso de ranolazina para el tratamiento de enfermedades cardiovasculares.
BR112013026644A2 (pt) método para a modulação da atividade de citocina
UA109359C2 (xx) Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном
MX2011012595A (es) Composicion farmaceutica que comprende el uso de derivados de prostaglandina para modular las funciones mediadas por claudina y el tratamiento de trastornos dermatologicos.
CY1114276T1 (el) Χρηση αιθυλεστερα εικοσαπενταενοϊκου οξεος για θεραπεια υπερτριγλυκεριδαιμιας
WO2009071725A3 (es) Utilización de valproato para el tratamiento del miedo y la fobia en sujetos con la enfermedad de alzheimer
TH139656A (th) เอสเทอร์โพรดรักซ์-)Ester-Pro-drugs) ของ [3-(1-(1H-อิมิดาซอล-4-อิล(เอทธิล (-2-เมทธิลฟีนิล] เมทธานอลสำหรับการรักษาโรคผิวหนัง และสภาวะทางผิวหนัง
UA53455U (ru) Способ лечения некоторых дерматозов
BR112015002384A8 (pt) combinações farmacêuticas compreendendo um inibidor de b-raf, um inibidor de egfr e, opcionalmente, um inibidor de pi3k-alfa, e seus usos".
BR112014033118A2 (pt) combinações farmacêuticas de um inibidor de cdk4/6 e um inibidor de b-raf
UA27832U (en) Method for treating dystrophic and vascular diseases of retina and optic nerve

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190207